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Abstract
Background: Candidemia is a major infectious complication of seriously immunocompromised patients.
In the absence of specific signs and symptoms, there is a need to evolve an appropriate diagnostic
approach. A number of methods based on the detection of Candida mannan, nucleic acid and (1,3)-beta-
D- glucan (BDG) have been used with varying specificities and sensitivities. In this retrospective study,
attention has been focused to evaluate the usefulness of two or more disease markers in the diagnosis of
candidemia.
Methods: Diagnostic usefulness of Platelia Candida Ag for the detection of mannan, Platelia Candida Ab
for the detection of anti-mannan antibodies, Fungitell for the detection of BDG, and of a semi-nested PCR
(snPCR) for the detection Candida species-specific DNA have been retrospectively evaluated using 32 sera
from 27 patients with culture-proven candidemia, 51 sera from 39 patients with clinically suspected
candidemia, sera of 10 women with C. albicans vaginitis, and sera of 16 healthy controls.
Results:  Using cut-off values recommended by the manufacturers, the sensitivity of the assays for
candidemia patients were as follows: Candida snPCR 88%, BDG 47%, mannan 41%, anti-mannan antibodies
47%, respectively. snPCR detected 5 patients who had candidemia due to more than one Candida species.
The sensitivities of the combined tests were as follows: Candida mannan and anti-mannan antibodies 75%,
and Candida mannan and BDG 56%. Addition of snPCR data improved the sensitivity further to 88%, thus
adding 10 sera that were negative by BDG and/or mannan. In clinically suspected, blood culture negative
patients; the positivities of the tests were as follows: Candida DNA was positive in 53%, BDG in 29%,
mannan in 16%, and anti-mannan antibodies in 29%. The combined detection of mannan and BDG, and
mannan, BDG and Candida DNA enhanced the positivity to 36% and 54%, respectively. None of the sera
from Candida vaginitis patients and healthy subjects were positive for Candida DNA and mannan.
Conclusion: The observations made in this study reinforce the diagnostic value of snPCR in the sensitive
and specific diagnosis of candidemia and detection of more than one Candida species in a given patient.
Additionally, in the absence of a positive blood culture, snPCR detected Candida DNA in sera of more than
half of the clinically suspected patients. While detection of BDG, mannan and anti-mannan antibodies singly
or in combination could help enhancing sensitivity and eliminating false positive tests, a more extensive
evaluation of these assays in sequentially collected serum samples is required to assess their value in the
early diagnosis of candidemia.
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Background
Candidemia is a major infectious and steadily increasing
complication of seriously immunocompromised patients
that is associated with high mortality rates [1-5]. Non-spe-
cific clinical presentation, low positivity of blood cultures
even in autopsy-proven cases and rapid course of the dis-
ease have necessitated the need for developing sensitive
methods for the early diagnosis of invasive candidiasis
[1,6]. Among the different approaches that have been
developed and evaluated in the recent years include detec-
tion of Candida  mannan [7,8], arabinitol [9-11], and
nucleic acids [12-15]. However, all these methods have
limitations of sensitivity and/or specificity. The recent
introduction of BDG detection assay, a fungus-specific
marker, has provided a new diagnostic tool with encour-
aging results [16-18]. This has encouraged the investiga-
tors to evaluate the usefulness of BDG in tandem of
mannan and/or DNA for the early and specific diagnosis
of invasive mycoses [19]. In this communication, we have
evaluated the diagnostic value of Candida species-specific
DNA, BDG, Candida mannan, and Candida anti-mannan
antibodies in sera samples obtained from culture-proven
candidemia patients and clinically suspected cases of can-
didiasis.
Methods
Patients and sera samples
Thirty-two sera from 27 culture-proven candidemia
patients, 51 from 39 clinically suspected blood culture
negative systemic candidiasis patients, 10 from Candida
vaginitis patients and 16 from healthy subjects with no
complaints of oral or vaginal Candida  infection were
included in the study. All the candidemia patients were
admitted to the intensive-care unit and other wards of
Mubarak Al-Kabeer Hospital, Kuwait for various condi-
tions (Table 1). According to the European Organization
for Research and Therapy of Cancer and Mycoses Study
Group (EORTC/MSG) consensus revised definitions draft
presented at ICAAC, 2005, all the patients yielding Cand-
ida species in blood cultures were considered as cases of
candidemia. Besides yielding Candida  species in blood
culture, the patients had suggestive signs and symptoms
of septicemia along with one or more risk factors, such as
prolonged use of broad-spectrum antibiotics, presence of
central venous catheter or extended period (> 2 weeks) of
hospitalization. The other risk factors included gastroin-
testinal surgical procedures (n = 6), chronic renal failure
(n = 3), multiple organ injury (n = 3), invasive urinary
tract manipulation (n = 3), diabetes mellitus (n = 2) and
pancytopenia (n = 2). In absence of microbiologic evi-
dence of candidemia, 39 patients were included in the
possible/suspected category of systemic candidiasis on the
basis of suggestive host and clinical criteria. The patients
included in this category had fever that did not respond to
4 days of broad-spectrum antibiotic therapy. In addition,
they had at least three of the following risk factors:
extended period of hospitalization (> 2 weeks), isolation
of Candida species from one or more anatomic sites, pres-
ence of intravenous catheter/line, recent history of a surgi-
cal procedure, and administration of immunosuppressive
therapy. Sera of healthy subjects were included as controls
to derive baseline values. All the sera were stored at -20°C
until used. The study was approved by the Committee for
Protection of Human Subjects in Research, Faculty of
Medicine. Kuwait University and informed written con-
sent was obtained from the patients involved in the study.
Candida species isolation and identification
Blood samples were processed for isolation of Candida
species by BACTEC 9240 system (Becton Dickinson, Par-
amus, N.J. USA) using aerobic culture bottles. Aliquots
from blood culture bottles yielding yeast growth were sub-
cultured on Sabouraud dextrose agar plates with chloram-
phenicol (40 mg/L). A single representative colony was
processed for identification by germ-tube test and Vitek 2
yeast identification system (bio Merieux Marcy l'Etoile,
France). In case of discrepant results with snPCR identifi-
cation, their identity was reconfirmed by ID 32C assimila-
tion profile.
Detection of Candida mannan
Mannan antigen was measured using a commercial sand-
wich immunoassay, Platelia Candida Ag (BioRad, Marnes
La Coquette, France). The test was performed according to
the instructions of the manufacturer. Briefly, each test
serum (300 µl) was mixed with 100 µl of the treatment
solution and placed in a boiling water bath for 3 minutes.
After centrifugation, the supernatant was used for further
testing. Fifty-µl of the conjugate and an equal amount of
the treated serum supernatant was introduced into micro-
titer plate wells pre-coated with anti-mannan monoclonal
antibody. After incubation at 37°C for 90 min and 5
washing steps, 200 µl of the substrate buffer was added to
each well, and the plates were incubated for 30 min at
room temperature. The enzymatic reaction was termi-
nated by adding the stopping solution and the optical
density was read at 450 nm using a Tecan Spectra (Aus-
tria) plate reader. The reactions were performed in dupli-
cates and each experiment included positive and negative
controls as well as a calibration curve, which was made
with a pool of normal human serum supplemented with
known concentrations of mannan ranging from 0.1 to 2
ng/ml.
Detection of Candida anti-mannan antibodies
Anti-mannan antibodies were measured using the Platelia
Candida Ab/Ac/Ak kit, a two-stage indirect immunoenzy-
matic assay (Bio-Rad, Marnes La Coquette, France). The
test was performed according to the manufacturer's
instructions. In brief, 100 µl of each test serum diluted 1/BMC Infectious Diseases 2007, 7:103 http://www.biomedcentral.com/1471-2334/7/103
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Table 1: Particulars of 27 blood culture-positive candidemia patients and results on detection of species-specific Candida DNA, (1,3)-
beta-D-glucan, mannan and anti-mannan antibodies by diagnostic kit cut-off value
Case no Age/sex Underlying 
condition
Blood culture Semi-nested 
PCR with 
serum
BDG (pg/ml) Mannan (ng/ml) Anti-mannan 
Abs (AU/ml)
1 88/F Septicemia, 
Chest infection
C. albicans C. albicans, C. 
parapsilosis
35 0.32 9.8
1b* 88/F Septicemia, 
Chest infection
C albicans C. albicans 53 0.32 11.2
2 49/F Chronic renal 
failure
C. albicans C. albicans 40 0.26 0.8
3 79/M Large bowel 
obstruction
C. albicans C. albicans 172 0.8 13.2
4 17/M Aseptic 
meningitis
C. albicans C. albicans 20 0.28 2.4
53 4 / M G u t  s u r g e r y C. albicans C. albicans 130 0.66 6.8
6 50/M Pancytopenia C. albicans C. albicans, C. 
parapsilosis
30 0.52 0.8
7 56/M Appendicular 
mass
C. albicans C. albicans 44 1.3 10.6
7b* 56/M Appendicular 
mass
C albicans C. parapsilosis 69 0.38 9.6
83 5 / M- C. albicans C. tropicalis 131 0.86 20.6
94 2 / M- C. albicans C. albicans 43 0.5 3
10 26/F Small bowel 
obstruction, 
pancreatitis
C. albicans C. albicans, C. 
parapsilosis
32 0.48 8
10b* 26/F Small bowel 
obstruction, 
pancreatitis
C. albicans -ve 21 0.22 34
11 22/F - C. albicans -ve 48 0.36 24.4
12 78/F Laparotomy C. albicans -ve 28 0.3 20.8
12b* 78/F Laparotomy C. albicans -ve 22 0.34 27.8
13 71/F Laparotomy C. albicans C. albicans, C. 
tropicalis
127 1.44 2
14 9mo/F Pneumonia C. albicans C. parapsilosis 112 3.19 1
15 68/M Bladder cancer C. albicans C. parapsilosis 157 0.36 35
16 58/M Renal failure C. albicans C. albicans 254 1.54 7
17 77/M Chest trauma C. albicans C. albicans 97 0.64 1.6
18 48/M Bronchopneum
onia
C. albicans C. albicans 321 0.24 23.8
19 20/F Meningitis C. parapsilosis C. albicans 32 0.34 11.2
20 80/M Urinary tract 
infection
C. parapsilosis C. parapsilosis 120 0.3 19.4
21 54/F Diabetes 
mellitus, LVF
C. parapsilosis C. parapsilosis 65 0.22 1.4
22 04/M Head injury C. parapsilosis C. albicans 20 0.28 2.2
23 6mo/F Pneumonia C. parapsilosis C. parapsilosis 101 0.62 2.2
24 80/M Chest infection C. tropicalis C. tropicalis, C. 
albicans, C. 
parapsilosis
47 0.48 7
25 41/M Polyarteritis 
nodusa
C. tropicalis C. tropicalis 115 2.8 1.4
25b* 41/M Polyarteritis 
nodusa
C. tropicalis C. tropicalis 108 0.4 19.4
26 74/M Jaundice, fever C. tropicalis C. parapsilosis 205 1.88 12.4
27 28/M Thrombocytop
enia
C. kruseii C. albicans 132 0.2 13.4
Age is expressed in years unless indicated. mo: months, LVF: left ventricular failure, BAL: broncho-alveolar lavage, M: male, F: female, * repeated 
specimen of the respective patient, – : not grown/information not available
Interpretation of results:
Mannan Ag: positive = > 0.5 ng/ml, intermediate = 0.25–0.5 ng/ml, negative = < 0.25 ng/ml; Anti-mannan antibodies: positive = > 10 AU/ml, 
intermediate = 5–10 AU/ml, negative = < 5 AU/ml; BDG: positive = = 80 pg/ml, equivocal = > 60 < 80 pg/ml, negative = < 60 pg/ml; positive results 
are shown in bold lettersBMC Infectious Diseases 2007, 7:103 http://www.biomedcentral.com/1471-2334/7/103
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6,400 was applied to each well of micro-titer plate wells
sensitized with C. albicans cell wall mannan and the plate
was incubated at 37°C for 1 h. After washing, 100 µl of the
conjugate was added and the plate was incubated at 37°C
for 1 h. After intensive washing, the reactions were
revealed by 30 min of incubation in the dark with 200 µl
of the substrate buffer. The enzymatic reaction was termi-
nated by adding the stopping solution and the optical
density was read at 450 nm using a Tecan Spectra plate
reader. The reactions were performed in duplicates and
each experiment included positive and negative controls
as well as standard serum diluted to give four range points
of 20, 10, 5, and 2.5 AU/ml for positive reference.
(1,3)-beta-D-glucan assay
The test was carried out using the glucan detection kit,
Fungitell (Associates of Cape Cod Inc., E. Falmouth, MA,
USA). The glucan standard provided in the kit was mixed
with reagent water to give a 100 pg/ml concentration. This
was further diluted to obtain glucan concentrations of 50,
25, 12.5 and 6.25 pg/ml. Five µl of the serum sample was
transferred to the designated wells of the micro-titer plate
and 20 µl of the blood treatment reagent (0.6 M KCl and
0.125 M KOH) was added to each well containing the
serum samples. The plate was shaken for 5 seconds and
incubated for 10 minutes at 37°C. Twenty-five µl of each
of the glucan standards (100, 50, 25, 12.5 and 6.25 pg/
ml) was added to the designated wells. The provided Fun-
gitell reagent was reconstituted with reagent water and
pyrosol reconstitution buffer and 100 µl of this solution
was added to each well. The plate was shaken for 5 sec-
onds in a Tecan Sunrise (Austria) plate reader before read-
ing at 405 nm every 1 minute for 40 minutes. The
concentration of BDG in the clinical samples was calcu-
lated in comparison with a kinetic curve derived from
known concentrations of glucan.
PCR study
Reference Candida strains were obtained from American
Type Culture Collection (ATCC, Manassas, Virginia, USA)
and included C. albicans (ATCC 90029), C. parapsilosis
(ATCC 10233), C. tropicalis (ATCC 750) and C. glabrata
(ATCC 90030). All yeast strains were stored at -20°C in
sterile distilled water. DNA was extracted from broth cul-
tures by the method of Lee [20] with an additional step of
DNA purification by extraction in phenol-chloroform
(24:1). DNA from serum was extracted using the QIAamp
DNA kit (QIAGEN) following the blood and body fluid
spin protocol. All pan-fungal and species-specific forward
and reverse primers as well as the DNA amplification
method was the same as mentioned by Ahmad et al. [13].
To detect amplified DNA fragments, agarose gel electro-
phoresis was performed using 3% agarose gels as
described previously [14]. The gels were exposed to UV
light and photographed. The sizes of the amplified DNA
fragments were identified by comparison with molecular
size marker DNA (100-bp DNA ladder, Invitrogen).
Interpretation of results and statistical analysis
The cut-off values recommended by the manufacturers for
each test were used for determining positive, equivocal/
intermediate and negative tests and were as follows: BDG,
≥ 80 pg/ml as positive, 60–79 pg/ml as equivocal and < 60
pg/ml as negative; mannan, > 0.5 ng/ml as positive, 0.25–
0.5 ng/ml as intermediate and < 0.25 ng/ml as negative;
anti-mannan Candida antibodies, > 10 AU/ml as positive,
5–10 AU/ml as intermediate and < 5 AU/ml as negative.
All positive assay results were considered as true positives
in patients with candidemia and also in clinically sus-
pected patients. Additionally, all values under the cut-off
values including doubtful results were considered as neg-
ative for calculation of sensitivity of the assays. Agreement
between the qualitative test results was assessed by use of
the kappa statistics. The p-values for the different tests
were calculated using the Independent samples T test,
Pearson's test and Z test for proportions using SPSS (Sta-
tistical package for social sciences) and Microstat.
Results
Detection and identification of Candida species by culture 
and snPCR
The particulars of 27 blood culture positive candidemia
patients with respect to age, sex, underlying conditions, as
well as results of detection of Candida DNA, BDG, and
Candida  mannan and anti-mannan antibodies are pre-
sented in Table 1. Eighteen were infected with C. albicans,
5 with C. parapsilosis, 3 with C. tropicalis and one with C.
krusei. snPCR results were positive in 25 (92.5%) candi-
demia patients. Among 32 sera samples examined from
27 patients, 4 sera samples originating from three patients
(Table 1, Case Nos. 10b, 11, 12 and 12b) were negative by
snPCR. In 7 patients (Case Nos. 8,14, 15, 19, 22, 26, 27)
Candida species isolated from blood cultures were identi-
fied differently by snPCR. The identity of Candida isolates
showing discordant results was re-confirmed by Vitek2
yeast identification system and/or Chromagar Candida. In
one patient (Case No. 7) while both the blood cultures
yielded C. albicans, the second serum sample was snPCR
positive for C. parapsilosis. In addition, snPCR detected 4
patients (Case Nos. 1, 6, 10, 13) with dual infection (3
with C. albicans and C. parapsilosis and one with C. albicans
and C. tropicalis), and one patient (Case No. 24) was pos-
itive for C. albicans, C. parapsilosis and C. tropicalis.
Candida mannan
Using a cut-off value of > 0.5 ng/ml for a positive mannan
test, the sensitivity and specificity in candidemia patients
were 41% and 100%, respectively. The quantities of man-
nan in positive serum samples ranged from 0.5 to 3.19
(mean ± SD = 1.29 ± 0.88) ng/ml) (Table 1).BMC Infectious Diseases 2007, 7:103 http://www.biomedcentral.com/1471-2334/7/103
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(1,3)-beta-D-glucan
Fourteen (52%) patients with proven candidemia were
positive for BDG test using a cut-off value of 80 pg/ml.
The amount of BDG in 15 positive serum samples ranged
from 97 to 321 pg/ml (mean ± SD = 152.13 ± 63.08 pg/
ml) (Table 1). The sensitivity and specificity of BDG test
were 47% and 100%, respectively.
Anti-mannan antibody
Using a cut-off value of > 10 AU/ml, the sensitivity of anti-
mannan antibody test was 47% with 100% specificity.
The antibody levels among the 15 positive sera samples
from 14 patients ranged from 10.6 to 35 (mean ± SD =
19.81 ± 8.05) AU/ml. The 11 patients who yielded a neg-
ative test for mannan antigen were positive for anti-man-
nan antibodies (Table 1).
Comparative analysis of Candida DNA, BDG, mannan and 
anti-mannan detection
Using cut-off values recommended by the manufacturers,
the comparative sensitivities of the assays for candidemia
patients were as follows: Candida snPCR 88%, BDG 47%,
mannan 41%, and anti-mannan antibodies 47% (Tables
1, 2 and Figures 1, 2, 3). Ten sera were positive for all the
three markers that is, Candida DNA, BDG and Candida
mannan (Figure 1) Fifteen sera samples positive for BDG
were also positive by snPCR. None of the four sera sam-
ples that were negative by snPCR (Table 1; 10b, 11, 12,
12b), were positive for BDG or mannan, but all of them
were positive for anti-mannan antibodies with values
ranging from 20.8 -34 AU/ml (Table 1). Likewise, the 5
sera samples that were positive for BDG and negative for
mannan were also uniformly positive for anti-mannan
antibodies (Table 1; 15, 18, 20, 25b, 27). Only 4 of the 15
sera positive for anti-mannan antibodies were concomi-
tantly positive for mannan. In general, increasing levels of
BDG were associated with increasing levels of mannan.
However, this correlation by Pearson test was not statisti-
cally significant (p = 0.078) (Figure 4). Candida  DNA
detection was found to be the most sensitive test (88%),
followed by BDG and anti-mannan antibodies, 47% each,
and mannan 41% (Figure 3). The combination of two
tests improved the sensitivity for diagnosing invasive can-
didiasis/candidemia as follows: mannan and anti-man-
nan antibodies by ELISA 75%, mannan and BDG 56%,
and mannan, BDG and Candida DNA 88% (Figure 3). The
combined sensitivities for mannan and anti-mannan anti-
bodies according to infecting Candida species were as: C.
albicans (n = 22), 77%, C. parapsilosis (n = 5), 60% and C.
tropicalis (n = 4), 75%, whereas for mannan and BDG,
these were 55%, 40% and 75%, respectively (Table 2).
Clinically suspected candidemia patients
In the clinically suspected, blood culture negative cate-
gory, 51 serum samples from 39 patients were tested. The
positivities of the tests were as follows: Candida DNA was
positive in 53%, BDG in 29%, mannan in 16%, and anti-
mannan antibodies in 29% (Fig. 5). The combined detec-
tion of mannan and BDG, and mannan, BDG and Cand-
ida  DNA enhanced the positivity to 36% and 54%,
respectively (Figure 5). Serum samples of 10 patients were
tested twice and of one patient thrice at different time
intervals. In addition to C. albicans, 2 serum samples were
positive for C. tropicalis and one for C. parapsilosis DNA. Of
the 27 snPCR positive sera, 8 were also positive for anti-
mannan, 5 for mannan and 6 for BDG (performed on 24
sera samples).
Venn diagram showing number of sera with positive results  in each combination of mannan, BDG and snPCR (n = 32) Figure 1
Venn diagram showing number of sera with positive results 
in each combination of mannan, BDG and snPCR (n = 32).
0 0
3 5 
10
0
Mannan +   BDG +
PCR + 
4 negative
10
Table 2: Comparative results of mannan antigen, anti-mannan antibodies and (1,3)-beta-D-glucan alone and in combination in proven 
candidemia patients according to the infecting Candida species
Candida species in 
blood culture
No of sera tested Number showing positive result by diagnostic kit value cut-off (%)
Mannan Ag Anti-mannan Abs BDG Mannan + anti-
mannan
Mannan + BDG
C. albicans 22 10 (45) 10 (45) 9 (41) 17 (77) 12 (55)
C. parapsilosis 5 1 (20) 2 (40) 2 (40) 3 (60) 2 (40)
C. tropicalis 4 2 (50) 2 (50) 3 (75) 3 (75) 3 (75)BMC Infectious Diseases 2007, 7:103 http://www.biomedcentral.com/1471-2334/7/103
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Regression analysis of glucan and mannan values in culture- proven candidemia patients Figure 4
Regression analysis of glucan and mannan values in 
culture-proven candidemia patients. (n= 32, r2 = 0.100, 
p = 0.078)
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Candida vaginitis patients and healthy controls
Sera from Candida vaginitis patients were uniformly nega-
tive for Candida DNA, BDG, and mannan (Figure 2). Sera
of two patients showed positive values for anti-mannan
antibodies (10 and 16.2 AU/ml) (Figure 2). None of the
test markers were positive in sera of 16 healthy controls
(Figure 2).
Discussion
Diagnosis of invasive infections due to Candida species
presents unique problems. Clinical and radiological signs
are non-specific or develop late in the course of the dis-
ease. Conventional diagnostic tests are insensitive and the
"gold standard" diagnostic procedures (histopathological
examination and cultures from deep tissues) require
aggressive approach, which is often not feasible due to
thrombocytopenia, and the critical condition of these
patients [21]. To overcome these limitations, assays for
the detection of Candida antibodies, antigen, BDG and
DNA have been developed and evaluated for the diagno-
sis of invasive candidiasis [8,16,22-28].
In the present study, we have retrospectively evaluated the
diagnostic value of Candida DNA, Candida manan, and
anti-mannan antibodies, and BDG individually and in
comparison with each other in patients who yielded Can-
dida species in blood cultures. snPCR has been success-
fully applied in the direct detection and species-specific
identification of four clinically important Candida species
(C. albicans, C. parapsilosis, C. tropicalis and C. glabrata) in
sera samples. While species-specific Candida  DNA was
detected in 28 (88%) of the 32 sera samples obtained
from 27 culture-proven candidemia patients, discordant
results in comparison with Vitek2 identification were
obtained in eight patients (Case Nos. 7b, 8, 14, 15, 19, 22,
26 and 27) (Table 1). This discrepancy in the results may
be attributed to the possibility that these patients proba-
bly had concomitant infection with two different Candida
species and only one of the infecting species was proc-
essed for identification by Vitek 2 method. Since we did
not use a differential medium, such as Chromagar Cand-
ida, for making sub-cultures from BACTEC blood culture
bottles, the possibility of missing one of the infecting spe-
cies (probably with fewer colonies) existed. Four of the
discordant results occurred between C. albicans and C. par-
apsilosis and one each between C. tropicalis and C. parapsi-
losis and C. krusei and C. albicans. Barring C. krusei, the
other three Candida species were included in the snPCR
protocol. Since some delay occurred between blood cul-
ture positivity and collection of serum samples, it is possi-
ble that detectable levels of the DNA of one of the two
infecting Candida species were not available in the circula-
tion when the blood was drawn for snPCR testing. This
may also explain the reason as to why sera of four culture-
positive candidemia patients (Cases Nos. 10b, 11, 12,
12b) were negative by snPCR. On the other hand, snPCR
detected 5 candidemic patients whose all tests were nega-
tive except snPCR (Cases 2, 4, 10, 22, 24) and 5 additional
patients (Case Nos. 1, 6, 10, 13 and 24) (Table 1), where
more than one Candida species was involved besides C.
albicans, and included C. parapsilosis in 4 and C. tropicalis
in 2. Case No. 24 yielded positive results for C. tropicalis
and C. parapsilosis besides C. albicans. These results sup-
port the previous reports that a reasonable proportion of
patients with candidemia may have infection with more
than one Candida species [13,29,30]. Since Candida spe-
cies vary in their antifungal susceptibility profiles, this
observation may be useful in administering appropriate
therapy.
Recent studies have suggested that the combined detec-
tion of mannan and anti-mannan antibodies considera-
bly improves the diagnosis of candidiasis [8,25,26]. While
individual sensitivity of the test for mannan and anti-
mannan antibodies in our study was only 41% and 47%
respectively, the combined detection increased the sensi-
tivity to 75% (Fig. 3). Sendid et al. [25] concluded that
irrespective of the Candida species causing the disease, the
combined sensitivity of mannan and anti-mannan anti-
body detection in candidiasis patients was > 80%. In our
study, the combined sensitivities of mannan and anti-
mannan antibodies for C. albicans, C. parapsilosis, and C.
tropicalis were 77%, 60% and 75% and for mannan and
BDG, these were 55%, 40% and 75%, respectively (Table
2). Additionally, there was also an inverse relationship
between mannan and anti-mannan antibody levels, but it
was not statistically significant (p = 0.063; data not
shown) perhaps due to limited number of samples tested.
Some recent studies have demonstrated the usefulness of
BDG estimation in the early diagnosis and management
of fungal infections including candidiasis [16,19,31-33].
In our study, the sensitivity and specificity of BDG at a cut-
off level of 80 pg/ml were 47% and 100%, respectively.
The positive sera samples showed a range of 97 to 321 pg/
ml (mean value 152.13 pg/ml). The sensitivity of BDG
detection for diagnosing invasive fungal infections in dif-
ferent group of patients has been reported to vary consid-
erably (50 to 100%), largely because of use of different
cut-off values (10 to 120 pg/ml) for a positive test [16-
19,31,34]. In a recent study, Pickering et al. [17] evaluated
39 sera samples from 15 patients with blood culture pos-
itive yeast infections using a cut-off value of 80 pg/ml.
Thirty (77%) samples were positive for BDG (range 84 to
1359 pg/ml), and 13 of the 15 patients had at least one
specimen positive. In a recent multi-center study of 107
patients with proven candidiasis, 81% had a positive
result for BDG at a cut-off of 60 pg/ml and 78% had pos-
itive results at a cut-off of 80 pg/ml [18].BMC Infectious Diseases 2007, 7:103 http://www.biomedcentral.com/1471-2334/7/103
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Our study is noteworthy in that it compared the diagnos-
tic value of BDG in comparison with mannan using a
quantitative EIA test in blood culture positive candidemia
patients. The combination of the two tests improved the
sensitivity to 56%. Our observation is in agreement with
an earlier study by Mitsutake et al. [32]. These authors
compared the specificities and sensitivities of enolase
antigen, mannan antigen, Cand-Tec antigen and BDG in
the diagnosis of 39 patients with candidemia. Using a cut-
off value of 60 pg/ml, the specificity and sensitivity of
BDG test were 84.4 and 87.5% respectively. The authors
suggested that combination of two diagnostic assays may
increase the accuracy of diagnosis of candidemia.
Recently, Ostrosky-Zeichner et al. [18] have investigated
the utility of the BDG assay in the diagnosis of fungal
infections using a case control methodology. Using a cut-
off value of 80 pg/ml, sensitivity and specificity of 64%
and 92% was reported, respectively, with a PPV of 89%
and NPV of 73%. However, in a subsequent analysis of
the data of this study [18], Upton et al. [37] suggested that
sensitivity and specificity of the test could heavily be influ-
enced by prevalence rate of the disease in the patient pop-
ulation. Therefore, the calculation of PPV and NPV results
from a population of selected case patients and
unmatched control subjects may not provide useful infor-
mation about the efficacy of the test. In an another study,
Pazos et al. [19] reported that BDG and galactomannan
exhibited similar in vivo kinetics in patients with invasive
aspergillosis, hence their combined detection not only
improved the specificity and PPV to 100% without affect-
ing the sensitivity and NPV, but was also useful in identi-
fying false positive reactions in each test. It seems that
same may also be true for Candida  mannan and BDG
kinetics in patients with invasive candidiasis, hence their
levels may increase or decrease in tandem. While
increased levels of BDG in individual patients in our study
were generally associated with increased levels of man-
nan, this correlation, however, was not significant by
Pearson test (p = 0.078, r2 linear = 0.1) (Figure 2). Never-
theless, the combined detection of mannan and BDG may
also be helpful in eliminating false positive reactions
which may occur in hemodialysis or ICU patients who
may also have been colonized with Candida  species
[35,36]. In this context, all our Candida vaginitis patients
were negative for BDG as well as Candida DNA and man-
nan. This is consistent with previous reports suggesting
that Candida colonization may not lead to a positive BDG
assay [16,19].
Our study has several limitations. Apart from the small
numbers of samples tested, most of the observations are
based on a single serum specimen obtained before initiat-
ing antifungal therapy. Additionally, there is no data
available about the delay that occurred in obtaining a pos-
itive blood culture or between blood cultures and serum
withdrawal for snPCR.
Conclusion
The observations made in this study reinforce the diag-
nostic value of snPCR in the sensitive and specific diagno-
sis of candidemia. Additionally, in the absence of positive
blood cultures, snPCR detected Candida DNA in sera of
more than half of the clinically suspected patients. While
detection of BDG, mannan and anti-mannan antibodies
singly or in combination could help enhancing sensitivity
and eliminating false positive tests, a more extensive eval-
uation of these assays in sequentially collected serum
samples is required to assess their value in the early diag-
nosis of candidemia and also for monitoring response to
antifungal therapy.
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